Table 1.
Baseline Characteristics of Female Study Population (n = 92)
| Baseline Characteristics | No. (%) |
|---|---|
| Age at enrollment, y | |
| 20–29 | 23 (25.0) |
| 30–39 | 39 (42.4) |
| 40–49 | 22 (23.9) |
| ≥50 | 8 (8.7) |
| Acyclovir trial arm | |
| Placebo | 50 (54.3) |
| Acyclovir | 42 (45.7) |
| ART regimen | |
| AZT/3TC/NVP | 77 (83.7) |
| CBV/EFV | 5 (5.4) |
| d4T/3TC/NVP | 6 (6.5) |
| TDF/3TC/NVP | 3 (3.3) |
| TVD/EFV | 1 (1.1) |
| Baseline CD4 count, cells/μL | |
| <200 | 38 (42.3) |
| 200–450 | 54 (58.7) |
| Baseline HIV viral load, copies/mL | |
| <10 000 | 14 (15.2) |
| 10 000–99 999 | 46 (50.0) |
| ≥100 000 | 32 (34.8) |
| BMI, kg/m2 | |
| <18.5 | 8 (8.7) |
| 18.5–24.9 | 66 (71.7) |
| ≥25 | 18 (19.6) |
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; AZT, zidovudine; BMI, body mass index; CBV, zidovudine-lamivudine; d4T, stavudine; EFV, efavirenz; NVP, nevirapine; TDF, tenofovir disoproxil fumarate; TVD, tenofovir disoproxil furminate-emtricitabine.